Feasibility Study of New MRI Protocol in Assessing Early Blood Brain Barrier Disruption (BBBD)in Related to Delay Brain Edema
NCT ID: NCT01830894
Last Updated: 2013-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
30 participants
INTERVENTIONAL
2013-04-30
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of the current study is to evaluate the feasibility of the BBB disruption detection method to predict delayed peri - hemorrhage edema.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characteristics of Blood- Brain Barrier Permeability in Neurological Patients
NCT00419874
MR Imaging Study of TBI in Children
NCT03034031
Study of Reserves After Traumatic Brain Injury
NCT01628003
MRI for the Early Evaluation of Acute Intracerebral Hemorrhage
NCT01689402
Evaluation of Blood Brain Barrier Permeability in Chronic Stroke
NCT01203800
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Evaluation and Correlation between the disruption in blood-brain-barrier and the development of secondary brain edema associated with brain damage by using MRI in patients with various types of intra-cranial bleeding .
Research team:
Main (Primary researcher):
Sagi Harnof MD , Neurosurgery department, Sheba medical center, Tel Hashomer
Secondary researchers:
Prof. David Tanne (M.D), Neurology department .
Dr. Yael Mardor (PhD), Advanced technology department.
Dr. Oded Goren (M.D), Neurosurgery department.
Dr. Masswadeh Ahmad (M.D), Neurosurgery Department.
Background :
Spontaneous brain hemorrhage is one of the most difficult issues in strokes concept regarding underlying pathology, reasons and treatment.
Etiology:
* General prevalence of about approximately 10-15% in all strokes.
* Mortality and morbidity associated with it are the most severe with mortality rates of up to 50-60%.
There are various pathologies thought to be responsible for bleeding, most commonly known to be :
hypertension, Angiopathies, amyloidotic or vascular problems and space occupying lesions.
Treatment process that takes place is very limited and most patients are treated only conservatively.
Cytotoxic brain edema that develops around the bleeding results usually from local cell damage and local pressure. It usually increases in the first days after bleeding and is considered to be one of the main causes of deterioration after cerebral hemorrhage .
Sub-dural cerebral hemorrhage is a common disease due to traumatic injury, often with serious consequences.
Regarding the natural history of subdural bleeding, not only It's believed to be difficult predicting the bleeding's course, but the risk to induce cerebral edema and later on to develop into chronic sub Dural bleeding is unpredictable as well .
Nevertheless chronic sub-dural bleeding is one of the most common cases seen in neurosurgery practice, But worthy to notify that only little is known about the pathogenesis of the disease, appearance of symptoms , preferable time for drainage and its complications .
Although hasn't been contributing much in clinical evaluation of stoke, MRI has a growing importance in the field of stroke lately .
In a previous neuro-imaging research that included patients after ischemic stroke it was shown that with an innovative methodology based on leakage extravasation) contrast agent in MRI which allows to map the entire brain with high resolution, we can easily evaluate the sensitivity disorder in BBB .
In 27% of patients who showed no anomalies at BBB in normal MRI, calculated maps with late leakage showed significant volumes of BBB opening ischemic areas.
MRI research Group in the Advanced Technology Center of the Sheba Medical Center has developed an innovative methodology based on leakage (extravasation) contrast agent that allows to map the entire brain with high resolution and high sensitivity to check and describe disorders BBB.
Data Acquisition:
MRI will be performed using the General Electric (GE) T3.0/1.5 with a standard head coil of 8 channels.
MRI scans will include high-resolution spin-echo T1-weighted MRI , acquired before and at several time points after injection (1, 12, 20, 23, 30, 70 minutes after injection).
T1-MRI may be done with Echo Time (TE) / Repetition Time (TR) = 22/240 ms, field of view 26 x 19.5 inch, 5/0.5 mm slice thickness and 512x512 - pixels.
To notify : T1-MRI data is acquired simultaneously with any conventional imaging protocol accepted at Sheba Medical center by routine practice. (Sheba's routine).
Type of study:
A prospective feasibility study performed on a group of patients with cerebral hemorrhage.
The purpose of the study:
1. Assess the ability to characterize quantitatively the BBB disruption around cerebral hemorrhage.
2. Find a correlation between the degree of BBBD immediately after bleeding and cerebral edema 3-5 days after bleeding.
3. Search for clinical correlation between the degree of BBBD immediately after the bleeding and the clinical course that follows it later on.
Methods:
This is a prospective study aimed to test the feasibility of using BBBD protocol in MRI in order to predict the development of edema and clinical deterioration.
Course of the experiment:
Once the -on call- neurosurgery resident is notified about a patient with spontaneous ICH he would contact any of the researchers to begin the screening process for participation in the study. Patients who had undergone intracranial hemorrhage (ICH) that was discovered in the past twelve hours will undergo a screening process performed by any of the researchers in order to determine whether or not they meet the inclusion criteria. Such patients may arrive from the emergency room, intensive care unit or any of the other wards in the hospital.
3\. An initial Baseline MRI is to be done:
1. for spontaneous ICH bleeding - within 6-24 hours from the bleeding.
2. for chronic sub dural bleeding - at the time of diagnosis .
3. for acute sub-dural bleeding - within 6-24 hours from the bleeding.
It should be emphasized that the purpose of the MRI is to assess the extent of BBBD and is intended for research purposes only. This MRI protocol does not allow complete diagnostic assessment. .
Whether the patient needs an accompanying doctor while in MRI or not, is solely determined by a researcher, depending on the patient's clinical situation.
4\. Clinical follow-up : neurological status, registration of National Institutes of Health Stroke Scale (NIHSS questionnaire).
a- for spontaneous bleeding - Daily monitoring \& registering National Institutes of Health Stroke Scale (NIHSS) for five consequent days. Additional clinical follow-up will be performed two weeks later.
b- for chronic or acute sub-dural bleeding follow up visit after 14 days.
5\. second MRI which serves as review :
1. for spontaneous intra-cranial bleeding: on the 3rd -5th day after bleeding.
2. For chronic sub Dural bleeding : within two weeks.
3. For acute sub Dural bleeding: within two weeks.
6\. Two months later, third MRI will be reviewed for all types of bleeding.
7\. Result - Analysis of the outcomes as follows:
Search correlation between BBBD and clinical status. Search BBBD correlation with hematoma growth.
Search correlation between BBBD and the development of cerebral edema.
Search correlation between BBBD and growth process of Chronic Subdural Hematoma (CSDH)
Search correlation between BBBD and the drainage of CSDH.
Search correlation between BBBD while Acute Subdural Hematoma (ASDH) is converted to CSDH.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
spontaneous ICH bleeding
An initial Baseline MRI is to be done within 6-24 hours from the bleeding. second MRI which serves as review - on the 3rd -5th day after bleeding
MRI
3 MRI on different times during the study for each arm.
chronic sub dural bleeding
An initial Baseline MRI is to be done at the time of diagnosis. second MRI which serves as review -within two weeks.
MRI
3 MRI on different times during the study for each arm.
acute sub-dural bleeding
An initial Baseline MRI is to be done within 6-24 hours from the bleeding. second MRI which serves as review - within two weeks.
MRI
3 MRI on different times during the study for each arm.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRI
3 MRI on different times during the study for each arm.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patient is able to sign the informed consent form.
* Spontaneous brain hemorrhage ICH in the last12 hours ( pre- admission,or sub- dural bleeding (whether acute or chronic ).
Exclusion Criteria
* The patient is too unstable to undergo MRI
* The patient is a candidate for surgery within 24 hours.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sheba Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Sagi Harnof
M.D.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sagi Harnof, MD
Role: PRINCIPAL_INVESTIGATOR
Neurosurgery department, Sheba medical center, Tel Hashomer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sheba medical center, Tel Hashomer
Ramat Gan, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHEBA-12-9889-SH-CTIL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.